Ningxia Zhongke Biotechnology Valuation
Is 600165 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 600165 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 600165 für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 600165 für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 600165?
Other financial metrics that can be useful for relative valuation.
What is 600165's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CN¥2.19b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 17.1x |
Enterprise Value/EBITDA | -95.3x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 600165's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2.4x | ||
688722 Beijing Tongyizhong New Material Technology | 4.5x | 28.2% | CN¥2.9b |
300839 Ningbo Bohui Chemical TechnologyLtd | 0.7x | 22.2% | CN¥1.9b |
003002 Shanxi Huhua Group | 2.3x | 12.6% | CN¥2.7b |
002917 Shenzhen King Explorer Science and Technology | 2.3x | 36.7% | CN¥3.0b |
600165 Ningxia Zhongke Biotechnology | 9x | n/a | CN¥2.2b |
Price-To-Sales gegen Gleichaltrige: 600165 ist auf der Grundlage des Price-To-Sales Verhältnisses (5.3x) im Vergleich zum Durchschnitt der Vergleichsgruppe (0.9x) teuer.
Price to Earnings Ratio vs Industry
How does 600165's PE Ratio compare vs other companies in the CN Chemicals Industry?
Price-To-Sales gegen Industrie: 600165 ist teuer, wenn man sein Price-To-Sales Verhältnis (5.3x) mit dem CN Chemicals Branchendurchschnitt (1.8x) vergleicht.
Price to Sales Ratio vs Fair Ratio
What is 600165's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 9x |
Fair PS Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Sales Fair Ratio von 600165 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.